
Acerca de
Program
9.00-9.05 Welcome & introduction - Harry Janssen
Liver tumors - Chair Dave Sprengers
9.05-9.35 Role of biomarkers in HCC surveillance - Xavier Verhelst
9.35-9.55 Role of SBRT - Alejandra Mendez Romero
9.55-10.15 MASLD and liver tumors - Willem Pieter Brouwer
10.15-10.30 Discussion + Q&A
10.30-11.00 Break
Interventional hepatology - Chair Anne van Eldere
11.00-11.30 New endoscopic procedures in hepatology - Jonel Trebicka
11.30-11.50 To scope or not to scope in cirrhotic patients? Raoel Maan
11.50-12.05 Discussion + Q&A
​
12.05-13.05 Lunch
​
Liver failure and liver transplantation / ACLF - Chair Caroline den Hoed
13.05-13.10 Solko Schalm Award Ceremony
13.10-13.40 Alcohol and liver transplantion - Marina Berenguer
13.40-14.10 ACLF: to transplant or not? Thierry Artzner
14.10-14.30 Loose ends on HCV management: vaccination, decompensation and transplantation - Jordan Feld
14.30-14.45 Discussion + Q&A
​
14.45-15.00 Break
​
Latest drugs in liver disease - chair Harry Janssen
15.00-15.20 Metabolic drugs in steatosis - Mariëtte Boon
15.20-15.40 New HBV and HDV treatment: viral suppression or cure? Milan Sonneveld
15.40-16.00 Developments in autoimmune liver diseases - Adriaan van der Meer
16.00-16.15 Discussion + Q&A
​​
16.15-16.20 Closing remarks - Harry Janssen
16.20 Drinks